Literature DB >> 7126008

Treatment of restless legs syndrome with levodopa plus benserazide.

S Akpinar.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7126008     DOI: 10.1001/archneur.1982.00510230065027

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


× No keyword cloud information.
  34 in total

1.  Myoclonus.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

2.  Ropinirole versus placebo in primary restless legs syndrome.

Authors:  John C Morgan; Kapil D Sethi
Journal:  Curr Neurol Neurosci Rep       Date:  2006-07       Impact factor: 5.081

Review 3.  Management of restless legs syndrome in patients on dialysis.

Authors:  Miklos Z Molnar; Marta Novak; Istvan Mucsi
Journal:  Drugs       Date:  2006       Impact factor: 9.546

4.  Efficacy and safety of pramipexole in restless legs syndrome.

Authors:  John C Morgan; Kapil D Sethi
Journal:  Curr Neurol Neurosci Rep       Date:  2007-07       Impact factor: 5.081

5.  Restless legs syndrome.

Authors:  C Bernick; L Z Stern
Journal:  West J Med       Date:  1986-08

6.  Restless legs syndrome.

Authors:  C Clough
Journal:  Br Med J (Clin Res Ed)       Date:  1987-01-31

7.  Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa.

Authors:  J Staedt; F Wassmuth; U Ziemann; G Hajak; E Rüther; G Stoppe
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 8.  The restless legs syndrome.

Authors:  W R Gibb; A J Lees
Journal:  Postgrad Med J       Date:  1986-05       Impact factor: 2.401

9.  Dopamine D2 receptor alteration in patients with periodic movements in sleep (nocturnal myoclonus).

Authors:  J Staedt; G Stoppe; A Kögler; D Munz; H Riemann; D Emrich; E Rüther
Journal:  J Neural Transm Gen Sect       Date:  1993

Review 10.  Treatment of restless legs syndrome.

Authors:  Cynthia L Comella
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.